Accessibility Menu
Evogene logo

Evogene(NASDAQ) EVGN

Market Cap$9.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-96%
5 Year-98%
1 Year-48%
1 Month+24%
$0.64
+6.48%
+0.04Today
After hours$0.70+$0.06 (+9.19%)
Evogene last closing stock price
MetricPriceDate
Last closeUSD 0.632026-08-10
Evogene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+17.97%USD 0.542026-08-03
1 month+23.5%USD 0.512026-07-10
3 month-16.91%USD 0.762026-05-12
Year to date-42.52%USD 1.102025-12-31
1 year-47.74%USD 1.212025-08-08
3 year-92.26%USD 8.172023-08-11
5 year-97.88%USD 29.802021-08-11
Since inception-95.55%USD 13.502008-03-05

Evogene Financials at a Glance

Market Cap

$9.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.84M

Net Income (TTM)

-$11.77M

EPS (TTM)

-$1.38

P/E Ratio

-0.46

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$0.64

Volume

7,324,132.718

Open

$0.71

Previous Close

$0.63

Daily Range

$0.56 - $0.80

52-Week Range

$0.37 - $1.50

Estimated Earnings Date

Aug 26, 2026

EVGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evogene

Evogene Ltd. is a computational biology firm focused on advancing products in human health and agriculture through its proprietary Computational Predictive Biology (CPB) platform. The company leverages deep biological insights, big data analytics, and artificial intelligence to develop innovative life-science solutions.

Products and Services
  • Seed traits and agricultural chemicals to enhance crop yields
  • Human microbiome-based treatments for various health conditions
  • Innovative medical cannabis products through strategic partnerships
Growth Outlook
  • Established partnerships with leading agricultural companies like BASF and Bayer
  • Focus on expanding product offerings in the human health sector
  • Potential for growth in the industrial applications segment with castor bean seeds
Financial Highlights
  • Recent quarterly revenue of $334,000, showing a steady increase
  • Cash and short-term investments totaled $13.05 million as of March 2026
  • Current ratio of 2.77 indicates strong liquidity position
Evogene Ltd. operates in three primary divisions: Agriculture, Human Health, and Industrial Applications. The Agriculture division focuses on improving plant yields through innovative seed traits and agricultural chemicals, targeting essential crops such as corn, soybean, and wheat. The Human Health segment is dedicated to developing microbiome-based treatments for conditions like immuno-oncology and gastrointestinal disorders. Additionally, the Industrial Applications division enhances castor bean seeds for various industrial uses. The company has established a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. Evogene has formed key partnerships and licensing agreements with major agricultural enterprises, which may enhance its market position and drive future growth. The recent financial data indicates a solid liquidity position, with a current ratio of 2.77, suggesting the ability to meet short-term obligations effectively. Overall, Evogene Ltd. presents a compelling opportunity for investors interested in the biotechnology sector, particularly in innovative solutions for agriculture and human health.
AI Generated • Aug 4, 2026

Industry

Biotechnology

Sector

Health Care

Employees

52

CEO

Ofer Haviv, CPA

Website

www.evogene.com

Headquarters

Rehovot, HM 7638517, IL

EVGN Financials

Key Financial Metrics (TTM)

Gross Margin

30.93%

Operating Margin

-757.22%

Net Income Margin

-639.39%

Return on Equity

937.72%

Return on Capital

-663.23%

Return on Assets

-65.77%

Earnings Yield

-2.17%

Dividend Yield

0.00%

Payout Ratio

-1.65%

Stock Overview

Market Cap

$9.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.80M

Volume

7.32M

Avg. Volume

1.83M

Financials (TTM)

Gross Profit

-$863.00K

Operating Income

-$14.16M

EBITDA

-$12.88M

Operating Cash Flow

-$11.73M

Capital Expenditure

-$21.29K

Free Cash Flow

-$11.75M

Cash & ST Invst.

$13.05M

Total Debt

$2.03M

Evogene Performance Analysis

Evogene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,675,00080.1%
20232023-12-31USD 5,640,000236.7%
20242024-12-31USD 5,577,000-1.1%
20252025-12-31USD 3,853,000-30.9%
Evogene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-63.8%
Q32025-09-30-64.7%
Q42025-12-310.6%
Q12026-03-316.4%
Evogene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -6.46-6.0%
20232023-12-31USD -5.23-19.1%
20242024-12-31USD -2.89-44.6%
20252025-12-31USD -1.08-62.8%
Evogene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-63.2%
Q32025-09-30171.0%
Q42025-12-31-238.6%
Q12026-03-311.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$334.00K

-86.3%

Gross Profit

$204.00K

-75.4%

Gross Margin

61.08%

N/A

Market Cap

$9.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$192.14K

N/A

Employees

52

N/A

Net Income

-$5.87M

-126.9%

EBITDA

-$1.82M

+6.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$13.05M

+32.5%

Total Debt

$2.03M

-84.3%

Accounts Receivable

$1.70M

-48.3%

Inventory

$175.00K

-91.9%

Long Term Debt

$1.38M

-28.4%

Short Term Debt

$654.00K

-94.1%

Return on Assets

-65.77%

N/A

Return on Invested Capital

-1.11%

N/A

Free Cash Flow

-$2.96M

+44.3%

Operating Cash Flow

-$2.95M

+43.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BOLTBolt Biotherapeutics, Inc.
$3.99-1.48%
MRKRMarker Therapeutics, Inc.
$1.15+2.68%
COCPCocrystal Pharma, Inc.
$1.08+1.89%
IMNNImunon, Inc.
$1.63+1.24%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About EVGN

What is the current price of Evogene?

Evogene is trading at $0.63 per share.

What is the 52-week range for Evogene?

Over the past 52 weeks, Evogene has traded between $0.37 and $1.50.

How much debt does Evogene have?

As of the most recent reporting period, Evogene reported total debt of $2.03M.

How much cash does Evogene have on hand?

Evogene reported $8.54M in cash and cash equivalents in its most recent financial results.

What is Evogene’s dividend yield?

Evogene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services